Skip to main content

Month: February 2023

PCI Biotech: Invitation to Q4 2022 results presentation

Oslo, Norway, 13 February 2023 – PCI Biotech (OSE: PCIB) invites to an online presentation of the company’s Q4 2022 interim report on Friday 17 February 2023, 08:30am – 09:30am CET (local time). The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session. The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset (CSO), and Morten Luhr (BD Manager), and the presentation will be held in Norwegian. The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com,...

Continue reading

Poultry Nutrition Market is Expected to Reach USD 21.15 Billion by 2028 at a CAGR of 5.37% from 2022–2028; Increasing Preference for Poultry Farming to Elevate the Market Growth

The poultry nutrition market is dynamic and highly competitive, with various players offering various products and services. As a result, businesses must have a well-informed marketing strategy to remain ahead of the competition. That’s where SkyQuest’s latest market research report comes in. This comprehensive report provides valuable insights into the latest market trends, demographic changes, and customer preferences, helping businesses develop a sound marketing plan and implement effective, successful strategies. Westford, USA, Feb. 13, 2023 (GLOBE NEWSWIRE) — The Asia Pacific region is poised to maintain its dominance in the poultry nutrition market, thanks to the growing trend of poultry farming in major agriculture-based countries. Such tremendous growth is driven by the increasing demand for meat and the poultry...

Continue reading

Europe Electric Car Market is Expected to Surpass USD 854.15 Billion by 2028 at an Impressive CAGR of over 29% from 2022-2028; Increasing Consumer Preference Backed by Government Incentives to Elevate the Market Growth

SkyQuest has provided in-depth insights into the Europe electric car market with its research report. The report provides a comprehensive overview of the market and its latest trends and advancements in technology. Additionally, the report features an analysis of market share, sales, revenue generation, funding trends, and the overall business environment. With a focus on the major players and their accomplishments, the report also highlights recent upgrades, new product introductions, growth opportunities, the competitive landscape, and market size. This comprehensive report provides valuable information for businesses looking to establish themselves in the growing market. Westford, USA, Feb. 13, 2023 (GLOBE NEWSWIRE) — Germany is leading the way in the Europe electric car market, with over 1.38 million plug-in vehicles registered....

Continue reading

Goal Acquisitions Corp. Announces Shareholder Approval to Extend Period to Consummate the Proposed Business Combination with Digital Virgo

AUSTIN, Texas, Feb. 13, 2023 (GLOBE NEWSWIRE) — Goal Acquisitions Corp. (Nasdaq: PUCK) (“Goal”), a publicly traded special purpose acquisition company, announced that on February 7, 2023 its shareholders approved an extension to extend the period of time to consummate an initial business combination to March 18, 2023, subject to extension by the Board of Directors for up to five additional thirty-day periods. More than 89% of shareholders voted in favor of the extension, 9,546,357 public shares remain outstanding, and Goal expects to have approximately $97,029,243 remaining in the trust account. As previously announced on November 17, 2022 and described in greater detail in a Current Report on Form 8-K filed by Goal with the Securities and Exchange Commission (the “SEC”) on November 17, 2022, Goal and Digital Virgo Group (“Digital...

Continue reading

HomeTrust Bancshares, Inc. Announces Completion of Merger with Quantum Capital Corp.

ASHEVILLE, N.C., Feb. 13, 2023 (GLOBE NEWSWIRE) — HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“HomeTrust”), the holding company of HomeTrust Bank, today announced that its merger with Quantum Capital Corp. (“Quantum”) was completed as of February 12, 2023. The merger was a stock and cash transaction valued at approximately $70.8 million (the “Transaction”). On a pro forma basis, the combined entity will hold assets of approximately $4.3 billion, including loans of $3.6 billion and deposits of $3.6 billion. “We are pleased to announce the completion of our merger with Quantum and can now officially welcome this talented group of bankers to the HomeTrust team,” said C. Hunter Westbrook, President and Chief Executive Officer of HomeTrust. “Very early in the process we realized Quantum had a culture similar to...

Continue reading

Victoria Gold: Notice of Expiry of Offer for ATAC Resources

WHITEHORSE, Yukon, Feb. 13, 2023 (GLOBE NEWSWIRE) — Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is providing notice that its proposed offer to ATAC Resources Ltd. (“ATAC”) will expire at the close of business on February 17, 2023. On January 12, 2023, Victoria submitted a non-binding proposal to acquire 100% of the issued share capital of ATAC. Victoria proposed to offer C$0.12 per ATAC share, payable in Victoria shares. On January 17, 2023, ATAC declined Victoria’s proposal. Following subsequent discussions between ATAC and Victoria and their respective advisors, ATAC formally confirmed its rejection of Victoria’s proposal on February 7, 2023. Victoria believes its offer is fair and generous consideration for ATAC shareholders. Victoria’s offer implies a premium of 85 percent to ATAC’s closing share price on February...

Continue reading

Astrotech Reports Second Quarter of Fiscal Year 2023 Financial Results

AUSTIN, Texas, Feb. 13, 2023 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for its second quarter of fiscal year 2023, which ended December 31, 2022. Financial Highlights & Recent Developments Astrotech’s consolidated balance sheet remains strong with $46.8 million in cash and liquid investments. Year-to-date revenue totaled $301 thousand and was generated by sales of TRACER 1000™ explosive trace detector (ETD), as well as recurring maintenance services and sales of consumables for the TRACER 1000. The decrease in revenue from the prior fiscal year is primarily the result of Astrotech shifting focus from the volatile ETD market to commercialization and marketing of the AgLAB 1000-D2. Year-to-date gross margin increased to 38% from 18%, an increase...

Continue reading

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

First subject enrolled into the OPMD clinical development program HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission. “In January, we were excited to announce the enrollment of the first OPMD patient into the natural history phase of the BB-301 development program, and the screening process has continued at a rapid pace. The enrollment of the first patient...

Continue reading

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Topline trial results expected mid-March 2023 NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist, being investigated as a potential treatment option for moderate to severe Vasomotor Symptoms (VMS) associated with menopause. Topline results from this trial are expected in mid-March 2023. The Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial of ACER-801 is designed to evaluate the safety, pharmacokinetics (PK) and efficacy of ACER-801...

Continue reading

Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States

RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market RevoMotion offers the industry’s smallest diameter threaded glenoid baseplate which preserves bone and enhances intraoperative flexibility The system’s two streamlined instrument trays are designed to drive efficiencies, reduce OR complexity, and simplify the procedure in both the hospital and ASC BEDFORD, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has commenced the limited market release of its new RevoMotion Reverse Shoulder Arthroplasty (RSA) System, with the first surgeries performed in the United States. The launch of the RevoMotion...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.